Federal Register / Vol. 84, No. 19 / Tuesday, January 29, 2019 / Notices 457 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of respondents Form name Number of 

respondents 

Number of 

responses 

per 

respondent 

Average 

burden 

per response 

(in hours) 

Hospital CEO/CFO .......................................... Annual Hospital Interview .............................. 598 1 2 

Jeffrey M. Zirger, 

Acting Lead, Information Collection Review 

Office, Office of Scientific Integrity, Office 

of Science, Centers for Disease Control and 

Prevention. 

[FR Doc. 2019–00214 Filed 1–28–19; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–19–1170; Docket No. CDC–2018– 

0113] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on the data 

collection project titled ‘‘Canine 

leptospirosis surveillance in Puerto 

Rico.’’ This surveillance project aims to 

characterize the epidemiology of canine 

leptospirosis, assess the applicability of 

canine Leptospira vaccines used in 

Puerto Rico, and determine potential 

rodent, livestock, and wildlife reservoirs 

for leptospirosis. Findings from the 

study will be used to develop 

recommendations for the prevention of 

leptospirosis in dogs, focus human 

surveillance efforts, and guide further 

investigations on leptospirosis in Puerto 

Rico. 

DATES: CDC must receive written 

comments on or before April 1, 2019. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2018– 

0113 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS–D74, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS– 

D74, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses. 

5. Assess information collection costs. 

Proposed Project 

Canine Leptospirosis Surveillance in 

Puerto Rico (OMB Control No. 0920– 

1170 Exp. Date 03/31/2019)— 

Revision—National Center for Emerging 

and Zoonotic Infectious Diseases 

(NCEZID), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention (CDC) Bacterial Special 

Pathogens Branch (BSPB) requests for 

approval of revisions to existing data 

collection tools used in active 

surveillance for canine leptospirosis in 

Puerto Rico. The methods for data 

collection have not changed. 

Active surveillance allows for the 

collection of prospective data on acute 

cases to determine the incidence and 

distribution of leptospirosis in dogs, 

assess risk factors for infection, 

characterize circulating Leptospira 

serovars and species, assess 

applicability of vaccines currently in 

use based on serovar determination, and 

assess rodent, livestock, and wildlife 

reservoirs of leptospirosis based on 

infecting serovars found in dogs. 

Findings from this study will aid in the 

development of evidence-based, 

targeted interventions for the prevention 

of canine leptospirosis, be used to focus 

human leptospirosis surveillance 

efforts, and guide future investigations 

on leptospirosis in humans and animals 

in Puerto Rico. 

The information collection for which 

approval sought is in accordance with 

BSPB’s mission to prevent illness, 

disability, or death caused by bacterial 

zoonotic diseases through surveillance, 

epidemic investigations, epidemiologic 

and laboratory research, training and 

458 Federal Register / Vol. 84, No. 19 / Tuesday, January 29, 2019 / Notices 

public education. Authorizing 

Legislation comes from Section 301 of 

the Public Health Service Act (42 U.S.C. 

241). Successful execution of BSPB’s 

public health mission requires data 

collection activities in collaboration 

with the state health department in 

Puerto Rico and with local veterinary 

clinics and animal shelters participating 

in the study. 

These activities include collecting 

information about dogs that meet the 

study case definition for a suspect case 

of leptospirosis seen at participating 

veterinary clinics and shelters. 

Participating veterinarians and their 

veterinary staff collect information by 

interviewing the dog owner (shelters are 

an exception as dog will not have an 

owner) and reviewing medical and 

administrative records, as necessary. 

Basic information about the 

participating sites will also be collected 

for study management and to enhance 

data analysis. 

Information will be collected using 

paper forms and provided in Spanish. 

Staff at participating sites find it easier 

to complete a paper copy when 

abstracting medical record information 

and interviewing owners for 

information about their dog’s risk 

factors and symptoms. Study 

coordinators will enter collected data 

into an electronic database. 

The types of information collected 

include information about the dog’s 

signalment, location of residence, 

environmental risk factors, vaccination 

history, clinical signs and symptoms, 

laboratory results, and clinical outcome. 

Approval of this revision ICR will allow 

BSPB to continue to collect information 

which can help inform animal public 

health and will help contribute to a One 

Health understanding of leptospirosis in 

Puerto Rico. 

BSPB estimates involvement of at 

least 411 respondents (a minimum 385 

from the general public and 26 

veterinarians and their veterinary staff) 

and estimates a total of 168 hours of 

burden for research activities each year. 

The collected information will not 

impose a cost burden on the 

respondents beyond that associated 

with their time to provide the required 

data. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

Veterinarians or veterinary staff ........ Enrollment Questionnaire (Attachment C).26 1 5/60 2 

Veterinarians or veterinary staff ........ Log Sheet (Attachment D) ............... 26 24 1/60 10 

Veterinarians or veterinary staff ........ Case Questionnaire (Attachment E) 26 24 10/60 104 

Dog owners (general public) ............. Case Questionnaire (Attachment E) 624 1 5/60 52 

Total ........................................... ........................................................... ........................ ........................ ........................ 168 

Jeffrey M. Zirger, 

Acting Lead, Information Collection Review 

Office, Office of Scientific Integrity, Office 

of Science, Centers for Disease Control and 

Prevention. 

[FR Doc. 2019–00276 Filed 1–28–19; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Molecular, Cellular 

and Developmental Neuroscience Integrated 

Review Group; Cellular and Molecular 

Biology of Neurodegeneration Study Section. 

Date: January 31–February 1, 2019. 

Time: 8:30 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Catamaran Hotel, 3999 Mission 

Boulevard, San Diego, CA 92109. 

Contact Person: Laurent Taupenot, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4183, 

MSC 7850, Bethesda, MD 20892, 301–435– 

1203, taupenol@csr.nih.gov. 

This meeting notice is being published less 

than 15 days in advance of the meeting due 

to the partial Government shutdown of 

December 2018. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: January 18, 2019. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2019–00203 Filed 1–28–19; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer 

Advisory Board. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The open 

session will be videocast and can be 

accessed from the NIH Videocasting and 

Podcasting website (http://

videocast.nih.gov). 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material,